Related Experiment Video
Updated: Mar 9, 2026

07:04
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
Published on: May 2, 2025
1.3K
Phase I Trial: SABR and Ipilimumab-Letter
Susan M Hiniker1, Sunil A Reddy2, Susan M Swetter3,4
1Department of Radiation Oncology, Stanford University Medical Center and Cancer Institute, Stanford, California. shiniker@stanford.edu.
Abstract
No abstract available in PubMed .

